ArticlemSphere2024
Short-chain fatty acids of various lengths differentially inhibit
Article in mSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 25 citations in OpenAlex.
- Gut microbiota-derived short-chain fatty acids (SCFAs): immunomodulatory effects and therapeutic potential in infections.Clinical microbiology reviews · 2026Review
- Microbiome features associated with persistent intestinal carriages of Escherichia coli ST131 in a Southeast Asian cohort study.Nature communications · 2026Article
- Infection control and anti-apoptotic effect of Lactobacillus paracasei derivatives on fibroblasts through modulation of BCL2 transcription.Archives of microbiology · 2026Article
- Metagenomic survey of pathogen prevalence in the infant gut.Scientific reports · 2026Article
- Metabolic reprogramming of the infant gut by bifidobacteria-based probiotics drives exclusion of antibiotic-resistant pathobionts.Cell reports. Medicine · 2026Article
- The Role of Gut Microbiota in Acute Myeloid Leukemia.Journal of clinical medicine · 2026Review
- Sustainable antibiotic reduction in poultry production with Pulsatilla saponins and herbal supplementation.Poultry science · 2026Article
- Gut-heart axis at high altitude: a dynamic mediator from hypoxic dysbiosis to adaptive cardioprotection.Frontiers in microbiology · 2026Review
- Modulating gut microbial biofilms for intestinal barrier repair: opportunities in nutritional intervention.Frontiers in nutrition · 2026Review
- Combination Therapy with Azithromycin andMicroorganisms · 2025Article
- Article
- Microbial profile of the appendix niche in acute appendicitis: a novel sampling approach.FEBS open bio · 2025Article
- Production and characterization of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) copolymers from a pre- fermented hardwood hydrolysate.Bioprocess and biosystems engineering · 2025Article
- The Role of Gut Microbiota in Modulating Immune Signaling Pathways in Autoimmune Diseases.Neuromolecular medicine · 2025Review
- Gut microbiota dysbiosis and systemic immune dysfunction in critical ill patients with multidrug-resistant bacterial colonization and infection.Journal of translational medicine · 2025Article
- Article
- Inhibition of levodopa metabolism to dopamine by honokiol short-chain fatty acid derivatives may enhance therapeutic efficacy in Parkinson's disease.Scientific reports · 2025Article
- Leveraging Organ-on-Chip Models to Investigate Host-Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease.Advanced healthcare materials · 2025Review
- The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases.Biomolecules · 2025Review
- Ecological dynamics of Enterobacteriaceae in the human gut microbiome across global populations.Nature microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The gut microbiota is inextricably linked to human health and disease. It can confer colonization resistance against invading pathogens either through niche occupation and nutrient competition or via its secreted metabolites. Short-chain fatty acids (SCFA) are the primary metabolites in the gut as a result of dietary fiber fermentation by the gut microbiota. In this work, we demonstrate that the interaction of single-species gut commensals on solid media is insufficient for pathogen inhibition, but supernatants from monocultures of these commensal bacteria enriched in acetate confer inhibition against anaerobic growth of the enteric pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.